The Russian government has authorised the use of an anti-malarial drug to treat coronavirus patients despite international concerns over its safety and effectiveness.
The government published an order late Thursday allowing the use of hydroxychloroquine on patients after China donated more than 68,000 packs of the tablets to Russia.
The order was published after President Vladimir Putin had a phone conversation with Chinese leader Xi Jinping on Thursday evening.
It said the drug would be distributed to hospitals that are caring for patients who have tested positive for coronavirus or are suspected of having it. It said the drug's safety and effectiveness will be monitored by the state health watchdog.
Hydroxychloroquine has been used for decades against malaria and is being tested worldwide against the virus along with another anti-malarial drug, chloroquine.
Both have potentially serious side effects, especially in high doses or when administered with other medications, and their use to treat the virus is still experimental, without having gone through exhaustive clinical testing.
Some see them as a potential weapon in the fight against the virus while there is still no proven cure or vaccine. Hydroxychloroquine has shown early promise against COVID-19 in small-scale studies in France and China to reduce virus levels among people badly infected.
US President Donald Trump has touted it as a coronavirus treatment and in the US a limited emergency-use authorisation has been granted to the drug.
But many scientists are urging caution until larger trials show whether it is safe and effective.
The European Medicines Agency has said that both chloroquine and hydroxychloroquine need to go through clinical trials and should not be used to treat virus cases unless there is a "national emergency.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
